Phio Pharmaceuticals Stockholders Approve Increase to Long-Term Incentive Plan

Phio Pharmaceuticals Corp. announced that stockholders approved an amendment to the company's 2020 Long Term Incentive Plan at the 2026 Annual Meeting of Stockholders held on September 28, 2026.

The amendment, which became effective immediately upon approval, increases the number of shares of common stock available for issuance under the plan by 1,500,000 shares. The total number of authorized shares under the plan is now 2,452,017 shares.

In addition to the incentive plan amendment, stockholders elected six directors to serve until the 2027 Annual Meeting of Stockholders. The directors elected were Robert J. Bitterman, Patricia A. Bradford, David H. Deming, Jonathan E. Freeman, Ph.D., Curtis A. Lockshin, Ph.D., and R. Todd Plott, M.D.

Stockholders also ratified the appointment of Grant Thornton, LLP as the company's independent registered public accounting firm for the year ending December 31, 2026.

At the close of business on the record date of August 4, 2026, the company had 11,617,250 shares of common stock issued and outstanding.